Clinical trials demonstrated potential therapeutic strategies for RUNX1 mutated hematologic malignancies. Based on the current RUNX1 roles in human hematopoiesis, various therapeutic options were developed. The gene discussed is RUNX1; the disease is hematologic disorder.